News

It’s common to feel nervous (and maybe even spaced out) when your doctor demonstrates how to inject yourself with ...
A new study published in the Journal of Perinatology is helping premature babies avoid blood transfusions, thanks to new ...
Bristol Myers Squibb's Opdivo has been approved in a subcutaneous injection formulation by the FDA, making treatment easier for patients and potentially adding years to the product's patent life.
Subcutaneous Opdivo showed comparable effectiveness, safety and tolerability to IV Opdivo in advanced clear cell renal cell carcinoma.
Hooven, Chairman and CEO of Enable Injections. “Our enFuse platform is uniquely positioned to address challenges in developing large-volume subcutaneous oncology drugs. This wearable delivery ...